UK markets close in 1 hour 9 minutes
  • FTSE 100

    7,012.37
    +64.38 (+0.93%)
     
  • FTSE 250

    22,204.98
    +37.84 (+0.17%)
     
  • AIM

    1,233.85
    -1.81 (-0.15%)
     
  • GBP/EUR

    1.1666
    +0.0029 (+0.25%)
     
  • GBP/USD

    1.4110
    -0.0034 (-0.24%)
     
  • BTC-GBP

    40,154.94
    +389.20 (+0.98%)
     
  • CMC Crypto 200

    1,532.99
    -30.84 (-1.97%)
     
  • S&P 500

    4,121.50
    -30.60 (-0.74%)
     
  • DOW

    34,085.10
    -184.06 (-0.54%)
     
  • CRUDE OIL

    66.38
    +1.10 (+1.69%)
     
  • GOLD FUTURES

    1,828.80
    -7.30 (-0.40%)
     
  • NIKKEI 225

    28,147.51
    -461.08 (-1.61%)
     
  • HANG SENG

    28,231.04
    +217.23 (+0.78%)
     
  • DAX

    15,191.71
    +71.96 (+0.48%)
     
  • CAC 40

    6,280.87
    +13.48 (+0.22%)
     

Global Toxoplasmosis Treatment Drugs Market to Surpass US$ 3,996.7 Million by 2027, Says Coherent Market Insights (CMI)

·4-min read

According to Coherent Market Insights, the global toxoplasmosis treatment drugs market is estimated to be valued at US$ 2,859.4 million in 2020 and is expected to exhibit a CAGR of 4.9% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Toxoplasmosis Treatment Drugs Market:

Key trends in the market are the increasing prevalence of HIV and other compromised immune systems diseases which can lead to toxoplasmosis, rising approval of the generic version of drugs.

Market players are actively launching generic versions of toxoplasmosis treatment drugs for cost effective and quality treatment. Moreover, the players are committed to offer new and improved products to address the critical unmet needs of patients. For instance, in February 2020, Cerovene Inc. obtained approval for generic Daraprim (pyrimethamine) tablet for treatment of toxoplasmosis from the U.S. Food and Drug Administration (FDA). The drug is used with combination of sulfonamide for treatment of toxoplasmosis bacterial infection.

Moreover, rising prevalence of HIV across the globe is increasing the risk of toxoplasma gonad infection due to less immune response in HIV infected patients. For instance, according to the World Health Organization (WHO), by the end of 2018, around 37.9 million people across the globe would have HIV, therefore it is expected to increase prevalence of toxoplasmosis infection among the global population.

Request for Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/4166

However, high cost of drugs for the treatment of Toxoplasmosis are expected to hinder the market growth. For instance, in August 2015, Turing Pharmaceuticals now Vyera Pharmaceuticals LLC acquired the U.S. rights for the Daraprim, a lifesaving drug for the treatment of Toxoplasmosis. Vyera immediately increased the price of Daraprim from US$17.50 to US$750 per tablet i.e. increase in price by 4000%. Although in January 2020, the Federal Trade Commission of the U.S. filed a complaint against the Vyera Pharmaceuticals LLC, regarding the price hike and signing the data blocking agreements preventing several distributors from selling Daraprim sales data to third-party data reporting companies.

Key Market Takeaways:

The global toxoplasmosis treatment drugs market is expected to exhibit a CAGR of 4.9% during the forecast period owing to the increasing research activities regarding toxoplasmosis, also receiving grants. For instance, in October 2020, Moredun Foundation received the grant of US$ 0.77 Mn (£0.56M), which would be used to determine how toxoplasmosis disease is caused in the warm blooded animals and transmitted through food, and discovery of drug and vaccine to treat the toxoplasmosis. Moredun research institute would work in collaboration with the Brazil based University of São Paulo, Newcastle University, and Biomathematics and Statistics Scotland for developing a host-specific system for determining the severity of T. gondii infection and predicting how the toxoplasmosis infection progress.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4166

Competitive Landscape:

Key players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.

Market Segmentation:

  • Global Toxoplasmosis Treatment Drugs Market, By Indication:

    • Chronic Toxoplasmosis Infection

    • Acute Toxoplasmosis Infection

  • Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:

    • Parenteral

    • Oral

  • Global Toxoplasmosis Treatment Drugs Market, By Drug Class:

    • Pyrimethamine

    • Spiramycin

    • Leucovorin

    • Sulfadiazine

    • Folic Acid

    • Other

  • Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • Global Toxoplasmosis Treatment Drugs Market, By Region:

    • North America

      • By Country:

        • U.S.

        • Canada

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210416005117/en/

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US
: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us:
LinkedIn | Twitter